COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04914832

marta nunes, PhD

marta.nunes@wits-vida.org

2021-06-07

Unknown

nonRCT

Non-randomized

Single group assignment

Open label

single-center

Prevention

inclusion criteria: - any individual aged 18 and older eligible to receive az1222 vaccine following the national immunization recommendations. - willing and able to provide informed consent.

- any significant acute or chronic medical condition that in the opinion of the vaccinator makes the participant unsuitable for participation in the study or jeopardises the safety of the participant. - participant reports being pregnant. - history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine. test negative vaccine effectiveness case-control study the study population consists of individuals presenting at the participating hospitals and health centres during the study period, who: either - are hospitalized (or died) for an illness consistent with possible covid-19. or (in case of other hospital controls) - presented to the emergency department (ed) for reasons other than a covid-19 like illness (e.g. trauma or elective surgery). and - meet the inclusion criteria. inclusion criteria: - ever eligible to receive az1222 vaccine following the national immunization recommendations prior to hospital admission. and - willing and able to provide informed consent.

1

Shabir Madhi

18

100

Swaziland

Healthy volunteers

N/A

600

To estimate the AZD1222 vaccine effectiveness;Vaccine effectiveness in HIV-uninfected

None

Phase 4

[{"arm_notes": "2;weeks1-10", "treatment_id": 161, "treatment_name": "Chadox1 ncov-19", "treatment_type": "Non replicating viral vector", "pharmacological_treatment": "Vaccine"}]